Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Andrew G. McIntosh, MD

Advertisement

Articles by Andrew G. McIntosh, MD

Crystal light - stock.adobe.com

Radical nephrectomy before or after systemic therapy for mRCC

ByAndrew G. McIntosh, MD
December 2nd 2020

Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.

Advertisement

Latest Updated Articles

  • Crystal light - stock.adobe.com
    Radical nephrectomy before or after systemic therapy for mRCC

    December 2nd 2020



Advertisement
Advertisement

Trending on Urology Times

1

Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026

2

Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC

3

LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC

4

Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC

5

Chad Ritch, MD, on using PSMA-PET to guide treatment decisions

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us